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Abstract
Young-onset hypertension has a stronger genetic component than late-onset counterpart; thus, the identification of genes
related to its susceptibility is a critical issue for the prevention and management of this disease. We carried out a two-stage
association scan to map young-onset hypertension susceptibility genes. The first-stage analysis, a genome-wide association
study, analyzed 175 matched case-control pairs; the second-stage analysis, a confirmatory association study, verified the
results at the first stage based on a total of 1,008 patients and 1,008 controls. Single-locus association tests, multilocus
association tests and pair-wise gene-gene interaction tests were performed to identify young-onset hypertension
susceptibility genes. After considering stringent adjustments of multiple testing, gene annotation and single-nucleotide
polymorphism (SNP) quality, four SNPs from two SNP triplets with strong association signals (2log10(p).7) and 13 SNPs
from 8 interactive SNP pairs with strong interactive signals (2log10(p).8) were carefully re-examined. The confirmatory
study verified the association for a SNP quartet 219 kb and 495 kb downstream of LOC344371 (a hypothetical gene) and
RASGRP3 on chromosome 2p22.3, respectively. The latter has been implicated in the abnormal vascular responsiveness to
endothelin-1 and angiotensin II in diabetic-hypertensive rats. Intrinsic synergy involving IMPG1 on chromosome 6q14.2-q15
was also verified. IMPG1 encodes interphotoreceptor matrix proteoglycan 1 which has cation binding capacity. The genes
are novel hypertension targets identified in this first genome-wide hypertension association study of the Han Chinese
population.
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Introduction
Hypertension is a common disorder that is prevalent in most
populations, especially in highly industrialized regions [1]. The
prevention and management of hypertension has become an
important public health issue in the world. The identification of
hypertension susceptibility genes and an understanding of the
hypertension genetic mechanism may contribute to the develop-
ment of genetic prevention, counseling and treatment for
hypertension in the future. Efforts to identify hypertension genes
have been ongoing for several decades [2]. Some susceptibility
genes have been located using different mapping strategies. One of
the mapping strategies is ‘‘candidate-gene linkage analysis’’. This
method is effective for mapping genes with large phenotypic effects
that follow Mendelian laws of inheritance using a large-pedigree
linkage approach, and its success in identifying novel hypertension
genes is best described by Lifton’s works [3,4]. Using this
approach, approximately 10 genes were linked to the causality
of hypertension, which account for only a small fraction of the
essential hypertension etiology. Another mapping strategy is
‘‘genome-wide linkage approach’’. This method, which uses
hundreds to thousands of short tandem-repeat polymorphisms
and a large number of families, has been used in various studies
that suggested multiple potential locations of hypertension genes
for further research; however, the indicated regions of interest are
often too broad and are not consistent across multiple studies [5].
Very few studies have fine-mapped the genes, not to mention
carrying out cross-verification of these genes [6].
Much hope has thus been placed on the state-of-the-art
genome-wide association study approach using a large number
of dense single-nucleotide polymorphism (SNP) markers. From
2006 to 2008, several dozen large-scale genome-wide association
studies were published tackling various complex diseases [7]. To
date, there have been only two large-scale genome-wide
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out by the Wellcome Trust Case Control Consortium (WTCCC)
[8,9]. Neither yielded apparent variants at the initial stage of data
analysis. The Family Blood Pressure Program tried to replicate the
top six SNPs identified by the WTCCC but failed to do so [10].
These frustrating findings of the above attempts underscore the
need for stringent phenotype definition and powerful statistical
gene mapping methods in genetic analyses of hypertension.
To increase the genetic contribution and homogeneity of the
study trait, here we focus on young-onset hypertension (YOH),
which has a stronger genetic component than its older counterpart
[11]. Although clinical profile and candidate gene studies have
sketched a blueprint for genetic susceptibility in YOH in the Han
Chinese population [12–15], meticulous dissection of YOH by a
systematic genome-wide association study has not been performed.
This study aims to identify YOH susceptibility genes for the Han
Chinese population based on a two-stage study design consisting of
a genome-wide association study (GWAS) and a confirmatory
association study (CMAS).
Materials and Methods
Study design and samples
We performed a two-stage case-control association scan,
consisting of a GWAS for the first stage and a CMAS for the
second stage, to identify YOH susceptibility genes. We obtained
complete genotypic and phenotypic data from 1,008 YOH
individuals and established immortalized cell lines from their
lymphocytes for the Academia Sinica Multi-Center YOH Genetic
Study. In addition, we also obtained genotypic and phenotypic
data from 1,008 normal controls from three projects: the Taiwan
Han Chinese Cell and Genome Bank [16], the Cardiovascular
Disease Risk Factor Two-Township Study [17] and the Nutrition
and Health Survey in Taiwan [18]. This study was approved by
the Internal Review Board of Academia Sinica. A written
informed consent was signed by every participant at his/her
initial clinic visit. All individuals in this study were Han Chinese.
In the first-stage association mapping, GWAS, 175 YOH
patients with normal body mass indices (,23 kg/m
2), triglyceride
levels (,150 mg/dl) and high density2lipoprotein cholesterol
levels (.40 mg/dl) were analyzed. A one-to-one match strategy
for age (65 years) and sex was applied to select controls (n=175)
from the Taiwan Han Chinese Cell and Genome Bank [16]. In
the second-stage association mapping, CMAS, a group-match
strategy balancing three age groups (20–32, 32–44, 44+) and two
gender groups was applied to select controls (n=833) for the
remaining 833 patients on whom genotyping was carried out for
the SNPs identified at the first stage. The 1,008 normal controls
consisted of 314 individuals from the Taiwan Han Chinese Cell
and Genome Bank [16], 551 individuals from the Cardiovascular
Disease Risk Factor Two-Township Study [17] and 143
individuals from the Nutrition and Health Survey in Taiwan,
2005–2008 [18]. The male-female ratio was 2.08 for both the case
and control groups. Mean age (standard deviation) was 42.4 (6.2)
for female cases, 40.2 (7.7) for male cases, 42.8 (6.7) for female
controls and 40.9 (8.3) for male controls.
Power calculation
Under certain given scenarios as described below, we calculated
power of our two-stage case-control association study by GaTS
software [19]. Given an additive-effect disease model with a
prevalence of 13.4% for YOH [18], a genetic relative risk of 2, and
a disease allele frequency of 0.2–0.4, the power of our two-stage
analysis was 0.87–0.90 for a stringent test size of 5.45610
27. The
power was reduced to 0.29–0.38, if the genetic relative risk was
reduced to 1.5. If the disease followed a multiplicative-effect model
with a disease prevalence of 13.4%, a genetic relative risk of 2, and
a disease allele frequency of 0.2–0.4, the power of our two-stage
analysis increased to 0.96–0.99 for a stringent test size of
5.45610
27. The power was reduced to 0.38–0.56, if the genetic
relative risk was reduced to 1.5.
Inclusion criteria and auxiliary measurements
Inclusion criteria for YOH patients were defined as follows: (1) a
systolic blood pressure (SBP)$140 mmHg and/or diastolic blood
pressure (DBP)$90 mmHg over a 2-month period or, for those
who were on anti-hypertensive medication, SBP/DBP$120/
80 mmHg at two consecutive visits over a 2-month period; (2)
an initial diagnosis of hypertension between 20 and 51 years of
age; (3) no secondary causes of hypertension (such as chronic renal
disease, renal arterial stenosis, primary aldosteronism, coarctation
of the aorta, thyroid disorders, Cushing’s syndrome and
pheochromocytoma), which were ruled out through extensive
clinical investigations (including blood chemistry, renal function
tests, endocrine procedures and abdominal sonogram); (4) a fasting
glucose level ,126 mg/dl and no previous diagnosis of diabetes
mellitus; (5) a body mass index ,35 kg/m
2; (6) having both sides
of parents and grandparents identifying themselves as Han
Chinese; (7) being a legal resident of Taiwan.
Standard protocols for blood pressure measurements established
by the Nutrition and Health Survey in Taiwan [18] were followed
by all above studies. Blood pressure was measured three times with
two consecutive pulse measurements in between using the Omega
1400 NBP (Invivo Research Laboratories Inc., Orlando, FL,
USA). The average of the last two blood pressure measurements
was used to confirm the hypertension status. In addition, personal
interviews administered by trained nurses ascertained information
on socio-demographics, lifestyle and personal habits (smoking,
drinking and physical activity) and medical history and medica-
tions. For each eligible subject, 17.5 ml of venous blood from an
antecubital vein was drawn into a Vacutainer(R) tube (BD,
Franklin Lakes, NJ, USA) for clinical chemistry, and 5 ml was
drawn into a sodium citrate2containing Monovette tube (Sarstedt
AG & Co., Postfach, Nu ¨mbrecht, Germany) for DNA extraction.
SNP genotyping
In the first-stage association mapping, GWAS, YOH cases
(n=175) and normotensive controls (n=175) were genotyped with
the Affymetrix Human Mapping 100K Set (Affymetrix, San
Diego, CA, USA), which contains 116,204 SNPs with a median
inter-marker distance of 8.5 kb and 92% genome coverage within
100 kb of a SNP. Genomic DNA was isolated from leukocytes
using a Puregene kit (Gentra Systems, Minneapolis, MN, USA) for
genomic DNA isolation. The DNA concentration was quantified
and adjusted to 50 ng/ml using a NanoDrop ND-1000 Spectro-
photometer (NanoDrop Technologies, DE, USA). Genotyping of
each individual was performed with 500 ng genomic DNA
according to the GeneChip Mapping Assay Protocol and the
BRLMM (Bayesian Robust Linear Model with Mahalanobis
distance classifier algorithm) was used to call genotype data.
In the second-stage association mapping, CMAS, the SNPs
identified in GWAS were genotyped with Sequenom MassArray
(Sequenom, San Diego, CA, USA) for 833 YOH patients and 833
normotensive controls. The DNA concentration of each individual
was measured fluorometrically and then diluted to 25 ng/ml using
the PicoGreen dsDNA quantification reagent (Molecular Probes,
Eugene, OR, USA). PCR primers and primer extension probes
were designed using SpectroDESIGNER software (Sequenom),
GWAS of YOH in Han Chinese
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generated by PCR-ABI 9700 thermocyclers (Applied Biosystems,
Foster City, CA, USA). PCR products were transferred from the
microplate to a 384-well MassARRAY using SpectroCHIP
(Sequenom). The mass spectrum from time-resolved spectra was
analyzed and recorded using a MassARRAY mass spectrometer
(Sequenom), and each spectrum was then quantified and called
using SpectroTYPER and SpectroREADER software (Seque-
nom), respectively.
Statistical methods
This study conducted a two-stage association study in humans
consisting of GWAS at the first stage and CMAS at the second
stage. The detailed procedures are described as follows.
First, we evaluated SNP/genotyping quality by examining the
genotyping call rate (GCR), the status of Hardy-Weinberg
Equilibrium (HWE) and the minor allele frequency (MAF). The
minimum GCR for 350 samples was 0.972. Using the ALLELE
procedure of SAS software (SAS Institute, Inc. Cary, NC, USA),
we examined HWE using the Markov-Chain Monte-Carlo exact
HWE test [20] with one million permutations. Among 112,990
autosomal SNPs, 410 deviated from HWE with a
2log10(pFDR).3 (pFDR is defined in Procedure 6); these were
excluded from further analysis. Then, 838 SNPs with a GCR,0.9
were excluded. Finally, 20,029 SNPs with a MAF,0.01 were also
removed. The remaining 91,713 SNPs were used for further
GWAS analysis.
Second, we evaluated population admixture of the Taiwanese
population by using STRUCTURE software [21] and genomic
control analyses [22]. For the former analysis, we considered the
number of populations was K=3 (Minna, Hakka and Mainlander)
under an admixture model. Admixture proportions of all samples
in normotensive group and hypertensive group were calculated
respectively using STRUCTURE software [21]. For the latter
analysis, variance inflation fraction, max{1, square(median of
trend test statistics)/square(0.675)}, was calculated by the CASE-
CONTROL procedure of SAS software (SAS Institute, Inc.).
Third, we performed genome-wide single-locus association tests
using exact conditional logistic regressions [23,24], where a
dichotomous disease status of YOH was regressed on SNP
genotypes in either a nominal genotype coding system (i.e., AA,
AB and BB) or an ordinal genotype coding system (i.e., 0, 1 and 2
of allele A). Genetic effects of SNPs were examined using one
million Monte Carlo samples generated from a hybrid network
and Monte Carlo algorithm [25,26] by the LOGISTIC procedure
of SAS software (SAS Institute, Inc.). Throughout this paper, we
use the term CLR-NOMINAL analysis to describe the procedure
of fitting a conditional logistic regression model to associate
hypertension with a nominal-genotype-coding variable; the term
CLR-ORDINAL analysis describes fitting the same model with an
ordinal-genotype-coding variable.
Fourth, we performed genome-wide multilocus association tests
using either the haplotype association test or p-value combination
test. The genome-wide haplotype association tests combined
haplotype trend regression [27] and a sliding-window procedure
to scan the human genome chromosome by chromosome.
Multiple moving window sizes of 3, 5, 7 and 9 SNPs were used.
Haplotype frequencies were estimated using the composite
haplotype method [28], which requires less computational time
than the expectation-maximization algorithm. Haplotypes with
low frequencies were excluded using three thresholds of minimum
haplotype frequencies, 0.01, 0.05 or 0.10. The analysis was carried
out using HelixTree software (Golden Helix, Inc. Bozeman, MT,
USA).
The genome-wide p-value combination test combined a
truncated product p-value procedure [29] and a sliding-window
procedure to scan the human genome chromosome by chromo-
some, where the p values were those obtained from the previous
genome-wide single-locus association tests (CLR-NOMINAL or
CLR-ORDINAL). Multiple moving window sizes of 3, 5, 7 and 9
were applied. The analysis was carried out using the PSMOOTH
procedure of SAS software (SAS Institute, Inc.).
Fifth, we performed genome-wide pair-wise SNP-SNP interac-
tion tests for all possible combinations by testing whether the odds
ratios for the combined genotypes significantly differed between
case and control groups. PLINK software [30] was used. SNP
pairs identified were further verified by exact conditional logistic
regression models with interactive covariate(s) based on one
million Monte Carlo samples, where both nominal and ordinal
genotyping coding systems were considered. Significance of an
interactive effect with four degrees of freedom for a nominal
genotyping coding system and an interactive effect with one degree
of freedom for an ordinal genotyping coding system were
examined by a type III analysis, respectively. The conditional
logistic regression analysis was run using the LOGISTIC
procedure of SAS software (SAS Institute, Inc.).
Sixth, we performed multiple testing corrections. Multiplicity of
testing was adjusted using either the false discovery rate (FDR)
[31], pFDR, or a stringent p-value threshold in various stages of
analyses. SNPs with 2log10(pFDR).3 in HWE tests were
excluded from the subsequent analysis. SNPs, haplotype sets and
SNP triplets with 2log10(pFDR).3 were considered significant for
marker-trait associations. SNP pairs with a 2log10(p).8 for
interaction were identified as significant interactive pairs. All of the
SNP markers identified by any of the GWAS procedures were
annotated using GENOWATCH software [32]. For those SNPs
with at least one gene located within 100 kb of the flanking
regions, the SNP-hypertension associations were further examined
with more samples in the CMAS.
CMAS was carried out with 1,008 YOH patients and 1,008
normotensive controls. We used two analysis strategies, indepen-
dent data analysis and joint data analysis. The fomer strategy was
to analyze only the independent samples in CMAS (i.e., 833 YOH
patients and 833 controls) and the later strategy was to analyze the
combined samples in GWAS and CMAS (i.e., 1,008 YOH
patients and 1,008 normotensive controls). Age and gender were
adjusted in the analyses. Genotyping quality control procedures
were identical to those used during the first stage. An
unconditional logistic regression model with either a nominal-
genotype-coding covariate (ULR-NOMINAL analysis) or an
ordinal-genotype-coding covariate (ULR-ORDINAL analysis)
was carried out. Association/interaction tests were performed to
confirm the previous findings in the GWAS. Odds ratios and the
corresponding 95% confidence intervals were calculated to
estimate the effect sizes of the identified SNPs. In addition, the
linkage disequilibria (LD) structure of the identified contiguous
SNPs was examined using the HAPLOVIEW software [33].
Haplotype-trait association was examined based on a likelihood
ratio test [34]. Ten thousand permutations were performed to
calculate empirical p values of overall tests and individual
haplotype tests.
Results
GWAS at the first stage
Using 91,713 SNPs with good quality (see the discussion of
statistical methods), we investigated marginal effects (genome-wide
single-locus association test), joint effects (genome-wide multilocus
GWAS of YOH in Han Chinese
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interaction test) of SNPs on YOH.
First, STRUCTURE software and genomic control analyses
were performed to evaluate population admixture/stratification.
The results from STRUCTURE shows that the overall admixture
structures in our case samples and control samples are very similar,
suggesting the admixture in our population should not cause
spurious association in our association study. In addition, the
genomic control analysis shows that the variance inflation fraction
was 1.097, close to 1, also suggesting the impact of population
admixture/stratification on our association study is not significant.
The conclusion is similar to the findings in the previous studies
[35–37].
Second, genome-wide single-locus association tests were
carried out to detect marginal genetic effects of YOH. Exact p
values were calculated for the CLR-NOMINAL and CLR-
ORDINAL analyses to associate YOH with SNPs. After applying
an FDR correction to the p values, no SNPs satisfied
2log10(pFDR).3 (see Figures S1(A) and S1(B)). That is, no
individual SNP was significantly associated with the status of
YOH in this study.
Third, we further examined the effects of multiple SNPs on
YOH by two types of genome-wide multilocus association
analyses: p-value combination analysis and haplotype analysis
with sliding windows of 3, 5, 7 and 9 SNPs. Because the analyses of
different window sizes identified similar association regions, here
we show only the results of window size 3.
The p-value combination analysis integrated p values from
either the CLR-NOMINAL or CLR-ORDINAL analyses. The
analyses identified 20 significant triplets of SNPs with
2log10(pFDR).3 (see Figures 1(A) and 1(B)). Numerical
results and gene information of anchor (central) markers of the
20 identified SNP triplets are summarized in Table 1. Among
them, 13 triplets were identified by one analysis and seven by two
analyses. Among the seven triplets identified by the two analyses,
we focused on the three triplets located in known or hypothetical
gene regions (bold in Table 1). Note that the unadjusted p values
(in 2log10 scale) of the three triplets were greater than 7. The first
triplet was rs9308945-rs6711736-rs6729869 on chromosome 2;
the second triplet was rs6711736-rs6729869-rs10495809 on
chromosome 2; the third triplet was rs10517739-rs1444280-
rs10517740 on chromosome 4. The two triplets on chromosome
2 contained two overlapping SNPs, forming a SNP quartet. Seven
distinct SNPs in the three SNP triplets were genotyped for more
samples with the Sequenom’s MassARRAY and further analyzed
statistically in a CMAS, which is described below. Genome-wide
haplotype trend regression was also carried out but did not identify
any windows (i.e., triplets of SNPs) with 2log10(pFDR).3 (see
Figures S2(A), S2(B) and S2(C)).
Fourth, the interactive effects of all possible pairs of SNPs (more
than 4.2 billion SNP pairs) were exhaustively examined.
Numerical results and gene information of the identified top 10
SNP pairs are summarized in Table 2. The 10 SNP pairs satisfied
the following two conditions: (1) the difference test of odds ratios
between case and control groups for the combined genotypes
showed 2log10(p).8 (see column ‘‘ORT’’ in Table 2) and (2) at
least one SNP from the pair was located in a gene region. Except
for SNP pair rs1526555-rs765899, the significance of the
remaining 9 SNP pairs was also confirmed using interaction tests
of a CLR-NOMINAL analysis (see column ‘‘Nominal’’ in
Table 2) and a CLR-ORDINAL analysis (see column ‘‘Ordinal’’
in Table 2) based on the same data, where significance of the
CLR-NOMINAL and CLR-ORDINAL analyses were evaluated
by considering an FDR correction of 10 replication tests. The
significance of the 10 SNP pairs was also re-examined in a CMAS,
the results of which are described below.
In summary, the GWAS identified three SNP triplets with p-
value combination tests and 10 pairs of SNPs with significant
interactive effects that are located in gene regions. The three
triplets contain seven distinct SNPs and the 10 interactive pairs
contain 16 distinct SNPs. All of the resulting 23 SNPs were
genotyped in the CMAS.
CMAS at the second stage
For confirmatory purposes, the 23 SNPs were genotyped for
833 YOH patients and 833 normal controls. Summary statistics
and p values of single-locus association tests based on the
independent samples (833 YOH patients and 833 normal controls)
and on the combined samples (1,008 YOH patients and 1,008
normal controls) are presented (see Table 3). Odds ratios and
95% confidence intervals were calculated based on either the
independent samples or the combined samples (see Table 4).
After considering a multiple testing correction (2log10(pFDR).3),
no significant results were found for single-locus association tests.
This result suggests that a single SNP may not be capable of
producing a detectable YOH-SNP association. This conclusion is
consistent with our GWAS findings.
Next, we verified the significant findings obtained from genome-
wide multilocus association tests and the interaction tests. We
included only SNPs that passed the quality criteria in the CMAS.
Among the 23 SNPs, two SNPs (rs10517740 and rs10500328) had
a GCR,0.9, and three SNPs (rs10517740, rs2206416 and
rs10500328) significantly deviated from HWE (see Table 3);
these were excluded from the subsequent analysis. In addition, one
SNP triplet (rs104517739, rs1444280 and rs10517740) on
chromosome 4 contained the poor quality SNP rs10517740,
resulting in the exclusion of two SNPs (rs104517739 and
rs1444280). On the other hand, an interactive SNP pair
(rs10488767-rs10505328) contained one of the three poor-quality
SNPs, resulting in the exclusion of a SNP (rs10488767). Therefore,
we examined only four distinct SNPs (rs9308945, rs6711736,
rs6729869 and rs10495809) for p-value combination and
examined 13 SNPs (rs618171, rs7805441, rs1115620,
rs10506451, rs2502397, rs1886985, rs6129969, rs2214310,
rs7950640, rs994531, rs1526555, rs2331706 and rs765899) for
genetic interaction. We carried out confirmation analyses on the
following three SNP groups: (1) four distinct SNPs resulting from
the two SNP triplets on chromosome 2, and (2) 13 distinct SNPs
resulting from 8 interactive SNP pairs. All results are summarized
in Table 5 and Table 6.
First, we confirmed the significance of the four contiguous SNPs
(rs9308945, rs6711736, rs6729869 and rs10495809) located in a
hypothetical gene on chromosome 2. They were examined by a p-
value combination analysis with a window size of 2, 3 and 4 SNPs.
The significance for each respective SNP was strengthened after
considering the join effect of multiple SNPs (see Table 5). The
same findings were observed for the independent samples and for
the combined samples using either the ULR-NOMINAL or the
ULR-ORDINAL analysis. For example, in the analysis of the
combined samples, the marginal p values of the ULR-NOMINAL
analysis of the four SNPs were 0.0007, 0.0004, 0.0017 and 0.0260,
respectively (see Table 3). P values were greatly reduced after
considering the truncated product p-value method for the SNP
pair, triplet and quartet. Results showed that 2log10(p) values of
SNP pairs rs9308945–rs6711736, rs6711736–rs6729869 and
rs6729869–rs10495809 were 5.4738, 5.1218 and 3.5135, respec-
tively; 2log10(p) values of SNP triplets rs9308945–rs6711736–
rs6729869 and rs6711736–rs6729869–rs10495809 were 7.1739
GWAS of YOH in Han Chinese
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rs9308945–rs6711736–rs6729869–rs10495809 was 7.8469 (see
Table 5). After applying an FDR correction to the p values, the
SNP pairs, triplets and quartet satisfied 2log10(pFDR).3.
We further examined this region by considering LD and
haplotype analyses. LD structures of the four SNPs in the case-
only group, the control-only group and the combined group were
highly consistent. The four SNPs formed a strong LD block where
Figure 1. Results of genome-wide p-value combination analysis using p values from CLR-NOMINAL or CLR-ORDINAL analyses. The y
axis denotes 2log10(pFDR), and the x axis denotes cumulative physical positions on autosomes. The red reference line signifies 2log10(pFDR)=3. (A)
Results of p-value combination tests based on p-values from a CLR-NOMINAL analysis; (B) Results of p-value combination tests based on p-values
from a CLR-ORDINAL analysis.
doi:10.1371/journal.pone.0005459.g001
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CHR RS PP GI CLR-NOMINAL CLR-NOMINAL CLR-ORDINAL CLR-ORDINAL
2log10(p) 2log10(pFDR) 2log10(p) 2log10(pFDR)
2 rs6711736 34196635 Hypothetical 7.48527 3.52284 9.16600 4.68070
rs6729869 34196845 Hypothetical 7.04924 3.16599 9.02237 4.66200
rs10495809 34216890 Intergenic 7.38445 3.46342 9.46051 4.79912
rs1346007 34217210 Intergenic 5.79457 2.39848 7.84643 3.82731
4 rs6854244 138479489 Intergenic 7.76575 3.52284 8.84525 4.65691
rs10519412 138487534 Intergenic 7.79596 3.52284 8.51803 4.40070
rs10517739 162515975 Intergenic 6.43381 2.75013 7.02313 3.10209
rs1444280 162516134 FSTL5 7.88286 3.52284 8.84119 4.65691
8 rs4737649 64515583 IFITM8P 7.79134 3.52284 4.31484 1.54609
rs1431587 64516073 IFITM8P 7.70481 3.52284 3.80069 1.31314
rs1367807 64544666 Intergenic 6.83890 3.05256 3.44477 1.13168
rs831738 70313702 Intergenic 7.49105 3.52284 3.65335 1.23307
rs705994 70313758 Intergenic 7.50762 3.52284 3.61202 1.21483
rs705993 70314229 Intergenic 7.53247 3.52284 3.62344 1.21852
9 rs945658 1606639 Intergenic 6.59932 2.86734 3.9664 3.82731
10 rs2620887 49730508 WDFY4 5.15365 1.88658 7.04094 3.10209
18 rs10513909 8326569 Intergenic 6.98389 3.13540 4.76805 1.76466
rs10513910 18326428 Intergenic 6.85253 3.05256 3.96647 1.38965
rs9284423 36256475 Intergenic 8.48521 3.52284 9.90126 4.93883
rs9304221 36256659 Intergenic 6.02669 2.40668 6.92917 3.04592
The p-value combination analysis with a window size of 3 identified 20 triplets of SNPs in GWAS. Chromosome (CHR), RS number (RS), physical position (PP) and gene
information (GI) of the anchor (central) marker of each SNP triplet are shown. The last four columns represent unadjusted p value (2log10(p)) and adjusted p value
(2log10(pFDR)) of the p-value combination analysis based on single-locus p values from a CLR-NOMINAL analysis [model:
logit{Prob(Y=YOH|I11,I12)}=a0+a116I11+a126I12] and a CLR-ORDINAL analysis [model: logit{Prob(Y=YOH|X)}=a0+a16X], where Y is YOH status, I1j is an indicator of the
three genotypes (j=1, 2) of a SNP and X is a variable for the number of reference alleles. Anchor markers that had 2log10(pFDR).3 for both tests and were located in
known or hypothetical gene regions are highlighted in bold font.
doi:10.1371/journal.pone.0005459.t001
Table 2. A list of SNP pairs identified by SNP-SNP interaction tests in GWAS.
First SNP in an interactive pair Second SNP in an interactive pair Interaction tests [2log10(p)]
CHR RS PP GI GCR MAF CHR RS PP GI GCR MAF ORT Nominal Ordinal
7 rs1526555 11579529 KIAA0960 99.4 0.140 14 rs765899 68033499 RAD51L1 92.0 0.326 8.9073 2.9786 5.0546
11 rs7950640 58620981 LOC643652 100 0.387 7 rs2214310 25152103 xC7orf9 99.7 0.454 8.7347 3.9040 5.7904
12 rs10506451 61520532 PPM1H 100 0.357 6 rs1115620 113578211 LOC643884 99.4 0.496 8.5318 4.2654 5.8117
11 rs7950640 58620981 LOC643652 100 0.387 7 rs994531 25152938 xC7orf9 99.4 0.441 8.3949 3.7367 5.6075
6 rs1886985 76773462 IMPG1 100 0.491 20 rs2206416 39994257 Intergenic 100 0.486 8.3879 4.7945 6.7676
11 rs10488767 109964045 ARHGAP20 100 0.317 16 rs10500328 5747879 Intergenic 100 0.404 8.2666 3.6095 5.6956
12 rs10506451 61520532 PPM1H 100 0.357 6 rs2502397 113569072 LOC643884 100 0.499 8.1975 4.0066 5.6377
1 rs618171 215537693 LOC643717 100 0.443 7 rs7805441 77766109 MAGI2 100 0.451 8.1824 3.5028 5.3108
6 rs1886985 76773462 IMPG1 100 0.491 20 rs6129969 39967987 Intergenic 99.1 0.419 8.1167 3.7163 6.1904
7 rs1526555 11579529 KIAA0960 99.4 0.140 14 rs2331706 68031318 RAD51L1 100 0.364 8.0217 3.1281 4.9362
Interactive SNP pairs are listed in their order of significance. For each SNP of an interactive pair, chromosome (CHR), RS number (RS), physical position (PP), gene
information (GI), genotyping call rate (GCR(%)) and minor allele frequency (MAF) are shown. Finally, the 2log10(p) value from three interaction tests is shown: (1) the
difference test of odds ratio (ORT), (2) an interaction test of the CLR-NOMINAL analysis [model:
logit{Prob(Y=YOH|I11,I12,I21,I22,I116I21,I116I22,I126I21,I126I22)}=a0+a116I11+a126I12+a216I21+a226I22+b16I116I21+b26I116I22+b36I126I21+b46I126I22] and (3) an
interaction test of the CLR-ORDINAL analysis [model: logit{Prob(Y=YOH|X1,X 2,X 16X2)}=a0+a16X1+a26X2+a36X16X2], where Y is YOH status, Iij is an indicator of the
three genotypes (j=1, 2) of SNP i (i=1, 2) and Xi denotes the number of reference alleles of SNP i (i=1, 2).
doi:10.1371/journal.pone.0005459.t002
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(see Figures S3(A), S3(B) and S3(C)). Haplotype-based
association tests for the two SNP triplets rs9308945-rs6711736-
rs6729869 and rs6711736-rs6729869-rs10495809 and for the SNP
quartet rs9308945-rs6711736-rs6729869-rs10495809 showed that
global p values of haplotype-trait association tests were 0.0010,
0.0057 and 0.0055, respectively.
For the SNP triplet rs9308945-rs6711736-rs6729869, two
haplotypes presented significantly different distributions between
case and control groups. Frequencies of haplotype A-G-T in
hypertensive and normotensive groups were 0.3368 and 0.3862,
respectively, with a p value of 0.0008 for the difference test.
Frequencies of haplotype G-A-A in hypertensive and normoten-
sive groups were 0.6349 and 0.5759, respectively, with a p value of
0.0001. In the SNP triplet rs6711736-rs6729869-rs10495809, two
significant haplotypes were identified. Frequencies of haplotype A-
A-A in hypertensive and normotensive groups were 0.4694 and
0.4252, respectively, with a p value of 0.0059. Frequencies of
haplotype G-T-G in hypertensive and normotensive groups were
0.3328 and 0.3803, respectively, with a p value of 0.0019.
Second, we investigated the 13 SNPs that consisted of 8
significant interactive pairs identified by our GWAS. None of the
13 SNPs showed a significant marginal effect (see Table 3). Only
the interactive effect of a SNP pair rs1886985-rs6129969 was
confirmed in the combined samples (see Table 6). SNP pair
rs1886985-rs6129969 had 2log10(p)=4.0000 for a ULR-NOM-
INAL analysis and 2log10(p)=2.3318 for a ULR-ORDINAL
analysis. P-values of the ULR-ORDINAL analyses satisfied
2log10(pFDR).3.
Discussion
Hypertension is a common complex disorder characterized by
multifactorial inheritance, polygenic effects and genetic heteroge-
neity. The complex etiology of hypertension has made it difficult to
map disease-related genes. To date, no high-impact genes have
been directly linked to the onset of hypertension. In this study, we
not only carefully selected the phenotype (i.e., by focusing on
YOH) but also employed statistical methods designed to increase
the power of our analysis and to overcome genetic complexity.
The type of statistical gene mapping method used in gene
mapping studies is critical for successfully identifying genes
responsible for complex disorders. The single-locus association
method, which is useful for the detection of marginal effects, may
not be sufficient for the investigation of joint effects and interactive
(synergic) effects of complex disorders. To increase the test power,
Table 3. A list of SNPs initially identified by GWAS and re-examined in CMAS.
M CHR RS NT GI Combined samples Independent samples
GCR MA:MAF HWE
ULR-
NOMINAL ULR-ORDINAL GCR MA:MAF HWE
ULR-
NOMINAL ULR-ORDINAL
P 2 rs9308945 A/G Hypothetical 99.8 A: 0.393 1.0000 0.0007 0.0002 99.8 A: 0.394 0.6162 0.0539 0.0215
P 2 rs6711736 A/G Hypothetical 97.3 G: 0.392 0.3921 0.0004 0.0001 96.8 G: 0.393 0.1690 0.0226 0.0130
P 2 rs6729869 A/T Hypothetical 99.7 T: 0.363 0.5964 0.0017 0.0011 99.6 T: 0.362 0.2330 0.0345 0.0589
P 2 rs10495809A/G Intergenic 99.4 A: 0.453 0.9480 0.0260 0.0076 99.3 A: 0.453 0.5784 0.3715 0.1607
P 4 rs10517739C/T Intergenic 99.6 C: 0.316 0.5590 0.6727 0.9571 99.5 C: 0.311 0.3964 0.0489 0.0368
P 4 rs1444280 C/G FSTL5 97.5 C: 0.310 0.3669 0.5331 0.8619 97.8 C: 0.304 0.2256 0.0121 0.0127
P 4 rs10517740G/T Intergenic 91.4 T: 0.210 ,0.0001 ,0.0001 ,0.0001 89.6 T: 0.200 ,0.0001 ,0.0001 ,0.0001
I 7 rs1526555 A/C KIAA0960 95.9 A: 0.130 0.0101 0.3549 0.1685 95.2 A: 0.128 0.0921 0.7118 0.4393
I 14 rs2331706 C/T RAD51L1 99.9 T: 0.377 0.8912 0.4841 0.2285 99.9 T: 0.380 1.0000 0.3090 0.1298
I 14 rs765899 C/T RAD51L1 98.7 T: 0.377 0.6309 0.4011 0.1873 99.5 T: 0.378 1.0000 0.3330 0.1383
I 11 rs7950640 C/G LOC643652 99.7 C: 0.363 0.7408 0.9408 0.8137 99.6 C: 0.357 0.8203 0.7638 0.5403
I 7 rs2214310 C/T xC7orf9 99.7 C: 0.482 0.6158 0.7633 0.6486 99.7 C: 0.488 0.8881 0.8882 0.9074
I 7 rs994531 A/G xC7orf9 99.6 A: 0.478 0.4090 0.8472 0.6270 99.6 A: 0.485 0.8385 0.9398 0.7262
I 12 rs10506451A/G PPM1H 99.7 A: 0.362 0.8935 0.1134 0.0418 99.6 A: 0.363 0.3631 0.1468 0.0719
I 6 rs1115620 A/T LOC643884 98.0 T: 0.482 0.5292 0.8051 0.5189 97.7 T: 0.477 0.5228 0.8794 0.8378
I 6 rs2502397 A/G LOC7805441 99.9 A: 0.488 0.6640 0.2685 0.1465 99.9 A: 0.485 0.5768 0.5201 0.2660
I 6 rs1886985 A/G IMPG1 99.9 G: 0.491 0.9494 0.8774 0.9232 99.8 G: 0.488 1.0000 0.9408 0.9257
I 20 rs6129969 C/T Intergenic 99.9 T: 0.392 0.2834 0.3593 0.3800 99.9 T: 0.385 0.0386 0.0539 0.7652
I 20 rs2206416 C/T Intergenic 98.7 C: 0.368 ,0.0001 0.7193 0.9571 98.4 C: 0.337 ,0.0001 0.0545 0.6498
I 11 rs10488767A/G ARGAP20 98.7 A: 0.285 0.4337 0.7580 0.4661 98.4 A: 0.278 0.9359 0.4576 0.3175
I 16 rs10500328A/G Intergenic 87.2 A: 0.158 0.0001 0.3558 0.2359 84.6 A: 0.096 0.0268 0.0407 0.0417
I 1 rs618171 A/G LOC643717 99.5 A: 0.464 0.2786 0.2278 0.1167 99.3 A: 0.468 0.3009 0.4699 0.3065
I 7 rs7805441 C/T MAGI2 99.7 T: 0.467 0.2573 0.1722 0.1993 99.6 T: 0.471 0.1860 0.3112 0.5076
For each SNP, the method used (M), chromosome (CHR), RS number (RS), nucleotide types (NT) and gene information (GI) are shown. The results for combined samples
and independent samples are shown as follows: (1) genotyping call rate (GCR(%)), (2) minor allele and minor allele frequency (MA:MAF), (3) p values of the exact HWE
test (HWE), (4) exact p value of the ULR-NOMINAL analysis [model: logit{Prob(Y=YOH|I11,I12,IGender,ZAge}=a 0+a116I11+a126I12+a26IGender+a36ZAge] and (5) exact p value
of the ULR-ORDINAL analysis [model: logit{Prob(Y=YOH|X,IGender,ZAge)}=a0+a16X+a26IGender+a36ZAge], where Y is YOH status, I1j is an indicator of the three genotypes
(j=1, 2) of a SNP, IGender is an indicator of gender, ZAge is a covariate for age, and X is a variable for the number of reference alleles.
doi:10.1371/journal.pone.0005459.t003
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multilocus association methods, including the p-value combination
approach [29], haplotype analysis [27,34] and interaction analysis
[23–26,30], to compensate for the limitations of the single-locus
association test and to examine fully the genetic complexity of
hypertension.
Table 4. Odds ratios and 95% confidence intervals of SNPs identified by a p-value combination method and a SNP-SNP interaction
analysis in GWAS.
M CHR RS NT GI Combined samples Independent samples
OR1 OR2 OR3 OR1 OR2 OR3
P 2 rs9308945 A/G Hypothetical 0.59 (0.45, 0.78) 0.84 (0.69, 1.02) 0.79 (0.69, 0.89) 1.07 (0.80, 1.44) 1.33 (1.00, 1.77) 0.85 (0.74, 0.98)
P 2 rs6711736 A/G Hypothetical 1.72 (1.31, 2.26) 1.42 (1.10, 1.85) 1.29 (1.13, 1.47) 1.51 (1.12, 2.02) 1.39 (1.05, 1.85) 1.20 (1.04, 1.38)
P 2 rs6729869 A/T Hypothetical 1.68 (1.26, 2.23) 1.50 (1.13, 1.98) 1.24 (1.09, 1.42) 1.46 (1.08, 1.99) 1.47 (1.08, 1.99) 1.15 (1.00, 1.32)
P 2 rs10495809 A/G Intergenic 1.40 (1.09, 1.80) 1.23 (1.00, 1.50) 1.19 (1.05, 1.34) 1.21 (0.92, 1.60) 1.11 (0.89, 1.39) 1.10 (0.96, 1.26)
P 4 rs10517739 C/T Intergenic 0.93 (0.68, 1.26) 1.06 (0.88, 1.27) 1.00 (0.87, 1.14) 1.22 (0.87, 1.72) 1.28 (1.05, 1.57) 1.17 (1.01, 1.36)
P 4 rs1444280 C/G FSTL5 0.94 (0.69, 1.28) 1.09 (0.90, 1.31) 1.01 (0.88, 1.16) 1.26 (0.89, 1.79) 1.36 (1.11, 1.67) 1.21 (1.04, 1.41)
P 4 rs10517740 G/T Intergenic 0.52 (0.37, 0.74) 2.59 (1.74, 3.86) 0.44 (0.37, 0.52) 0.53 (0.37, 0.78) 5.27 (3.24, 8.56) 0.39 (0.32, 0.47)
I 7 rs1526555 A/C KIAA0960 1.18 (0.67, 2.06) 1.17 (0.94, 1.46) 1.14 (0.95, 1.36) 1.26 (0.67, 2.39) 1.06 (0.83, 1.36) 1.08 (0.89, 1.33)
I 14 rs2331706 C/T RAD51L1 0.85 (0.65, 1.12) 0.92 (0.71, 1.20) 0.93 (0.81, 1.05) 0.80 (0.59, 1.07) 0.87 (0.65, 1.16) 0.90 (0.78, 1.03)
I 14 rs765899 C/T RAD51L1 0.85 (0.65, 1.12) 0.95 (0.73, 1.24) 0.92 (0.81, 1.04) 0.81 (0.60, 1.09) 0.89 (0.67, 1.20) 0.90 (0.78, 1.04)
I 11 rs7950640 C/G LOC643652 1.02 (0.77, 1.34) 1.03 (0.86, 1.25) 1.02 (0.89, 1.16) 1.07 (0.78, 1.46) 1.08 (0.88, 1.33) 1.05 (0.91, 1.21)
I 7 rs2214310 C/T xC7orf9 1.06 (0.82, 1.35) 1.08 (0.88, 1.33) 1.03 (0.91, 1.17) 1.01 (0.77, 1.33) 1.06 (0.84, 1.33) 1.01 (0.88, 1.16)
I 7 rs994531 A/G xC7orf9 1.06 (0.83, 1.36) 1.06 (0.86, 1.30) 1.03 (0.91, 1.17) 1.05 (0.80, 1.38) 1.02 (0.81, 1.29) 1.03 (0.90, 1.17)
I 12 rs10506451 A/G PPM1H 1.34 (1.01, 1.77) 1.11 (0.92, 1.34) 1.14 (1.01, 1.30) 1.36 (1.00, 1.86) 1.07 (0.87, 1.32) 1.14 (0.99, 1.32)
I 6 rs1115620 A/T LOC643884 0.92 (0.71, 1.18) 0.95 (0.76, 1.18) 0.96 (0.85, 1.09) 0.98 (0.74, 1.29) 1.03 (0.81, 1.33) 0.99 (0.86, 1.13)
I 6 rs2502397 A/G LOC7805441 1.21 (0.94, 1.54) 1.03 (0.83, 1.27) 1.10 (0.97, 1.24) 1.17 (0.89, 1.54) 1.05 (0.84, 1.33) 1.08 (0.94, 1.24)
I 6 rs1886985 A/G IMPG1 1.01 (0.79, 1.29) 0.96 (0.77, 1.19) 1.01 (0.89, 1.14) 0.99 (0.75, 1.29) 0.96 (0.76, 1.22) 0.99 (0.87, 1.14)
I 20 rs6129969 C/T Intergenic 0.93 (0.72, 1.22) 1.07 (0.83, 1.39) 0.95 (0.83, 1.07) 1.07 (0.80, 1.44) 1.33 (1.00, 1.77) 0.98 (0.85, 1.13)
I 20 rs2206416 C/T Intergenic 0.98 (0.79, 1.22) 1.08 (0.87, 1.33) 1.00 (0.90, 1.11) 0.89 (0.70, 1.14) 1.27 (0.99, 1.63) 0.97 (0.87, 1.09)
I 11 rs10488767 A/G ARGAP20 1.12 (0.81, 1.55) 1.04 (0.87, 1.25) 1.05 (0.92, 1.21) 1.26 (0.88, 1.82) 1.02 (0.84, 1.26) 1.08 (0.93, 1.26)
I 16 rs10500328 A/G Intergenic 0.92 (0.59, 1.41) 0.85 (0.67, 1.07) 0.90 (0.76, 1.07) 0.95 (0.45, 1.98) 0.68 (0.51, 0.92) 0.78 (0.62, 0.99)
I 1 rs618171 A/G LOC643717 0.81 (0.64, 1.04) 0.96 (0.78, 1.18) 0.91 (0.80, 1.03) 0.86 (0.66, 1.13) 0.99 (0.79, 1.25) 0.93 (0.81, 1.07)
I 7 rs7805441 C/T MAGI2 1.16 (0.90, 1.49) 0.95 (0.76, 1.19) 1.09 (0.96, 1.23) 1.08 (0.82, 1.42) 0.91 (0.71, 1.16) 1.05 (0.91, 1.20)
For each SNP, the method used (M), chromosome (CHR), RS number (RS), nucleotide types (NT) and gene information (GI) are shown. Two genotypic odds, OR1 and OR2,
from the ULR-NOMINAL analysis [model: logit{Prob(Y=YOH|I11,I12,IGender,ZAge)}=a0+a116I11+a126I12+a26IGender+a36ZAge] and one allelic odds ratio, OR3, from the ULR-
ORDINAL analysis [model: logit{Prob(Y=YOH|X,IGender,ZAge)}=a0+a16X+a26IGender+a36ZAge] were calculated, where Y is YOH status, I1j is an indicator of the three
genotypes (j=1, 2) of a SNP, IGender is an indicator of gender, ZAge is a covariate for age, and X is a variable for the number of reference alleles. The results for combined
samples and independent samples are shown.
doi:10.1371/journal.pone.0005459.t004
Table 5. Confirmatory p-value combination analysis.
CHR SNP pair/triplet/quartet Combined samples Independent samples
ULR-NOMINAL ULR-ORDINAL ULR-NOMINAL ULR-ORDINAL
2log10(p) 2log10(p) 2log10(p) 2log10(p)
2 rs9308945 - rs6711736 5.4738 6.5331 1.3426 2.8468
2 rs6711736 - rs6729869 5.1218 5.8471 2.4989 1.5654
2 rs6729869 - rs10495809 3.5135 4.1433 1.1672 1.0110
2 rs9308945 - rs6711736 - rs6729869 7.1739 8.3979 2.1520 2.4655
2 rs6711736 - rs6729869 - rs10495809 5.8055 6.9586 2.1520 1.3721
2 rs9308945 - rs6711736 - rs6729869- rs10495809 7.8469 9.5155 1.9102 2.2028
SNP pairs, triplets and quartets that were identified by the p-value combination method in GWAS were verified in CMAS. Truncated product p-value statistics were
calculated by combing single p values from the previous single-locus ULR-NOMINAL analysis or ULR-ORDINAL analysis in CMAS. The exact p values (in 2log10 scale) for
the combined and independent samples are shown.
doi:10.1371/journal.pone.0005459.t005
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GWAS, we conducted a two-step genome-wide interaction
analysis to examine all possible pair-wise SNP-SNP interactive
effects. The first step applied a computationally efficient algorithm,
a difference test of odds ratios in hypertensive group and
normotensive group [30], to scan all possible pair-wise SNP-
SNP interactive effects. A large significance threshold of
2log10(p).8 was considered to control false positive. The second
step further verified the identified interactive effects using exact
conditional logistic regressions [23–25], which was computation-
ally intensive but accurate even for sparse data. In general, the
two-step procedure helps to reduce but may not exclude all false
positive due to 4.2 billion of tests were conducted in the first step.
A verification of the identified interactive effects in a CMAS
becomes critically important.
An important issue is to consider population admixture/
stratification, which may cause spurious association, in popula-
tion-based case-control studies. This study analyzed Han Chinese
samples in the Taiwanese population. In addition to 2 to 3%
aborigine people and foreign residents, the Taiwanese population
consists of the three major Han Chinese subgroups: Minnan
(70%), Hakka (13%) and Mainlanders (14%). Previous studies
showed that the high homogeneity of genetic distribution and
linkage disequilibrium structure among the three Han Chinese
subgroups relative to the Caucasian population. An impact of
population admixture on the results of case-control association
studies for the Taiwan Han Chinese population is small [35–37].
Our population admixture analyses using genome-wide SNP
markers also suggested the same conclusion.
This study is the first two-stage GWAS for YOH in the Han
Chinese population. We successfully identified novel genetic
variants associated with YOH as well as those with interactive
effects by applying a p-value combination analysis and a pair-wise
interaction analysis. At the first stage, GWAS identified two
significant SNP sets that were located in gene regions by using
conditional logistic regressions in conjunction with a p-value
combination test. SNP quartet rs9308945-rs6711736-rs6729869-
rs10495809 located on chromosome 2p22.3 was re-confirmed in
the second-stage analysis. Several studies found suggestive linkage
signals on chromosome 2p. In particular, HERITAGE Family
Study [38] and NHLBI Family Blood Pressure Program [39]
showed suggestive evidence at 2p22.3 for African Americans. The
quartet was 219 kb, 322 kb, 457 kb, and 495 kb downstream of
LOC344371 (hypothetical gene), MYADML (pseudo gene),
FAM98A (hypothetical protein), and RASGRP3, respectively.
RAS Guanyl Nucleotide-releasing protein 3 is a member of the
RAS subfamily of GTPases which functions in signal transduction
as GTP/GDP-regulated switches and serves as RAS activators.
Inhibition of RAS-GTPase signaling by chronic FPTIII treatment
in streptozotocin-induced diabetic spontaneously hypertensive rats
could ameliorate abnormal vascular responsiveness to endothelin-
1, angiotensin II in isolated carotid artery. Moderate reduction on
mean arterial blood pressure was also observed. Whether it is
RASGRP3 that involves in the YOH development and how the
discovered locus on 2p22.3 is connected await for further
functional studies.
Furthermore, GWAS also identified eight interactive SNP pairs
that passed SNP quality examination and were located in gene
regions. SNP pair rs1886985-rs6129969, which showed a
significant pair-wise interaction in associating with YOH, was
re-confirmed in the second-stage analysis. SNP rs1886985 is
located in IMPG1 on chromosome 6, and rs6129969 and
rs2206416 are located in an intergenic region on chromosome
20. IMPG1, which is located on 6q14.2-q15, encodes interphotor-
eceptor matrix proteoglycan 1, which may participate in retinal
adhesion and in maintaining photoreceptor viability [40]. IMPG1
contains 17 exons, including an alternatively spliced exon 2 [41]. A
Leu579Pro mutation in IMPG1 may have a causal role in benign
concentric annular macular dystrophy based on a linkage study of
a large Dutch family [42]. No association has previously been
found between IMPG1 and hypertension or related traits. Gene
IMPG1 has rat homologue. The gene ID is 66014 for IMPG1 with
respective to Rattus norvegicus.
We carried out a preliminary gene expression study comparing
pooled samples from three SHR and from three WKY rats at 4,
12, 26 and 38 weeks of age [43]. The use of SHR and WKY rats
was approved by the Academia Sinica Institutional Animal Care
and Utilization Committee. cDNA was hybridized with Nimble-
Table 6. Confirmatory interaction analysis.
The first SNP in an interactive pair The second SNP in an interactive pair Combined samples Independent samples
CHR RS NT GI CHR RS NT GI ULR-NOMINAL ULR-ORDINAL ULR-NOMINAL ULR-ORDINAL
2log10(p) 2log10(p) 2log10(p) 2log10(p)
1 rs618171 A/G LOC643717 7 rs7805441 C/T MAGI2 1.2890 1.9355 0.1516 0.0295
6 rs1115620 A/T LOC643884 12 rs10506451 A/G PPM1H 0.8380 1.8210 0.0427 0.0225
6 rs2502397 A/G LOC7805441 12 rs10506451 A/G PPM1H 0.6946 1.5200 0.1375 0.1086
6 rs1886985 A/G IMPG1 20 rs6129969 C/T Intergenic 4.0000 2.3318 1.2248 0.5629
7 rs2214310 C/T xC7orf9 11 rs7950640 C/G LOC643652 0.3310 0.7582 0.2480 0.7878
7 rs994531 A/G xC7orf9 11 rs7950640 C/G LOC643652 0.4148 0.8589 0.2426 0.6214
7 rs1526555 A/C KIAA0960 14 rs2331706 C/T RAD51L1 1.4622 2.1612 0.1350 0.0956
7 rs1526555 A/C KIAA0960 14 rs765899 C/T RAD51L1 1.3439 2.0410 0.1430 0.0753
For each SNP pair, chromosome (CHR), RS number (RS), nucleotide types (NT) and gene information (GI) are shown. Based on combined samples or independent
samples in CMAS, the interactive effect was examined using a ULR-NOMINAL analysis [model: logit{Prob(Y=YOH|I11,I 12,I21,I22,I116I21,I116I22,I126I21,I126I22,IGender,ZAge)}
=a 0+a116I11+a126I12+a216I21+a226I22+b16I116I21+b26I116I22+b36I126I21+b46I126I22+c6IGender+d6ZAge] or a ULR-ORDINAL analysis [model: logit{Prob(Y=YOH|X1,X2,X16
X2,IGender,ZAge))}=a0+a16X1+a26X2+a36X16X2+c6IGender+d6ZAge], where Y is YOH status, Iij is an indicator of the three genotypes (j=1, 2) of SNP i (i=1, 2), IGender is an
indicator of gender, ZAge is a covariate for age, and Xi denotes the number of reference alleles of SNP i (i=1, 2). The exact p values (in 2log10 scale) for the combined and
independent samples are shown.
doi:10.1371/journal.pone.0005459.t006
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analyzed with Gene Spring 7.3.1 (Agilent Technologies, Palo
Alto, CA, USA). The IMPG1 mRNA in SHR rats was 3.12-fold
higher than that of WKY rats at 4 weeks prior to the blood
pressure elevation in SHR rats, but not at other time points
suggesting its potential involvement in the early phase of
hypertension development. Proteoglycans are a major component
of the animal extracellular matrix and may be present in many
adult tissues including blood vessels [44] and nervous tissue [45]. It
is capable of binding cations and its synthesis is affected by cation
status [46]. IMPG1 expression may modify blood vessel structure
and affect the activity and stability of proteins and signaling
molecules within the matrix. In-depth functional studies are,
however, required to examine how this gene interactively exerts its
effects in humans.
In this study, we applied significance criteria 2log10(pFDR).3
and 2log10(p).8 for the genome-wide association/interaction
tests to reduce false-positive and false-discovery rates. In addition,
only significant SNPs, haplotypes and interactions that were
located in the region of known genes with potential biological
implications were further verified in the CMAS. The use of such
criteria may have resulted in a failure to identify biologically
relevant SNPs with a relatively small effect. Therefore, it may be
worthwhile to examine more SNPs in CMAS in the future by
altering the criteria of significance in the GWAS. For example, we
found two SNPs with 2log10(p).5, neither of which was
significant if an FDR correction was considered in single-locus
association. The first SNP, rs1010330 on chromosome 2, had a
2log10(p) of 5.5229 and 6.0000 for CLR-NOMINAL and CLR-
ORDINAL analyses, respectively. There have been no genes
identified near this SNP. The second SNP, rs864603 on
chromosome 21, had a 2log10(p) of 5.2218 and 5.5229 for
CLR-NOMINAL and CLR-ORDINAL analyses, respectively.
SNP rs864603 is located in gene SYNJ1, and the 100-kb flanking
region also contains C21orf59 and OR7E23P. These two SNPs may
be investigated further using additional samples and denser SNP
chips. The second example includes the 20 significant SNP triplets
identified in at least one of the GWAS analyses (CLR-NOMINAL
and CLR-ORDINAL). Only the three SNP triplets that were
significant in both types of analyses were verified. It would also be
worthwhile to verify the other SNP triplets that were significant in
only one kind of analysis, since each type of regression model has
its unique genetic meaning.
This study can be improved by recruiting more samples and
using denser SNP chips. Using CaTs [19], we provided an
approximate estimate of power for our two-stage association study.
In general, the two-stage association study had sufficiently high
power to detect SNP loci with a large main effect (e.g., genotype
relative risk .2). However, our association study had reduced
power because of the relatively small sample size of 175 case-
control pairs in the first stage GWAS. Some small-effect YOH loci
may have been missed despite of the higher sample size/power in
the second stage CMAS. More samples should be recruited for our
next genome-wide scan. However, due to the reasonable sample
size for the CMAS, the findings on the YOH-associated genes
should be real. On the other hand, this genome-wide study was
conducted based on data from the Affymetrix Human Mapping
100K Set. The results can be improved upon by using denser SNP
chips, such as the Affymetrix 500K/Array6.0 gene chips and
Illumina 550K/1M bead chips. We anticipate that more potential
loci may emerge when a denser chip is used with a larger number
of samples.
YOH is a common disorder with a complex disease etiology
that involves biologically important variants with minor to
moderate effects. A single-locus association test is limited in its
power to discover this type of common disease variant. This
phenomenon was also observed in our study, where no single
SNPs were identified as significantly important variants associated
with YOH. To overcome the difficulty of identifying common
variants that are associated with YOH, we performed several
multilocus association tests and interaction tests and successfully
identified some novel YOH disease genes. The success of this study
highlights the importance of using sophisticated statistical
association methods in addition to traditional single-locus
association tests. By using different methodological constructions,
the multilocus association tests and interaction analyses were able
to detect genes involved in joint and interactive models,
respectively. The employed p-value combination method (i.e.,
truncated product p values) utilizes the accumulated significant
association signals from proximal SNP markers, which is useful for
genetically mapping gene regions containing multiple SNPs that
are actually associated with YOH. Haplotype analysis relies on
linkage disequilibrium and is more powerful for discovering gene
regions containing specific YOH-related haplotypes or haplotype
combinations. Interaction analysis is especially designed for
detecting combinations of SNPs that act together through
pathways or in regulated mechanisms, even though they are
located in remote regions or on different chromosomes. These
methods provide complementary information for gene mapping.
More methods that handle genetic heterogeneity and complexity
should be developed to utilize genomic information fully for gene
mapping.
Replication of the novel findings is an important issue in
association studies. Our CMAS has successfully replicated several
SNP loci identified by our GWAS based on the same Taiwanese
population. In future, further confirming the results from
independent populations helps strengthen the credibility of our
findings scientifically [47]. We are working on the replicating
studies from independent populations by the following two ways.
First, we have collaborated with a Hong Kong young hypertension
study group to replicate our results. The study will help replicate
our findings from a same Han Chinese population with various life
styles and environment. Second, we are applying the data of
hypertension GWAS of the Wellcome Trust Case Control
Consortium. The study will help validate our results in a non-
Han Chinese population. In addition to replication studies, we are
also conducting a microarray gene expression study to examine
the mRNA-level transcriptional difference of the identified genes.
Supporting Information
Figure S1 Results of genome-wide single-locus association
analysis. The y axis denotes 2log10(pFDR) and the x axis denotes
cumulative physical positions on autosomes. Different colors and
symbols show the results on different chromosomes. (A) Results
based on a CLR-NOMINAL analysis. (B) Results based on a
CLR-ORDINAL analysis.
Found at: doi:10.1371/journal.pone.0005459.s001 (0.28 MB TIF)
Figure S2 Results of genome-wide haplotype trend regression
analysis. The y axis denotes 2log10(pFDR) and the x axis denotes
cumulative physical positions on autosomes. Results of haplotype
trend regression analyses for different minimum haplotype
frequencies are showed: (A) ,0.01, (B) ,0.05 and (C) ,0.10.
Found at: doi:10.1371/journal.pone.0005459.s002 (0.08 MB TIF)
Figure S3 LD structures of SNPs rs9308945, rs6711736,
rs6729869 and rs10495809 in control, case and combined groups.
The LD block contains four SNPs. The pairwise D9 and
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PLoS ONE | www.plosone.org 10 May 2009 | Volume 4 | Issue 5 | e5459frequencies of major haplotypes are shown: (A) LD structure in
control group, case group and combined group, (B) haplotype
frequencies in control group, case group and combined group.
Found at: doi:10.1371/journal.pone.0005459.s003 (0.11 MB TIF)
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